↓ Skip to main content

PLOS

Removal of Hepatitis C Virus-Infected Cells by a Zymogenized Bacterial Toxin

Overview of attention for article published in PLOS ONE, February 2012
Altmetric Badge

Mentioned by

twitter
1 X user
patent
3 patents
facebook
2 Facebook pages

Readers on

mendeley
48 Mendeley
Title
Removal of Hepatitis C Virus-Infected Cells by a Zymogenized Bacterial Toxin
Published in
PLOS ONE, February 2012
DOI 10.1371/journal.pone.0032320
Pubmed ID
Authors

Assaf Shapira, Shiran Shapira, Meital Gal-Tanamy, Romy Zemel, Ran Tur-Kaspa, Itai Benhar

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and has become a global health threat. No HCV vaccine is currently available and treatment with antiviral therapy is associated with adverse side effects. Moreover, there is no preventive therapy for recurrent hepatitis C post liver transplantation. The NS3 serine protease is necessary for HCV replication and represents a prime target for developing anti HCV therapies. Recently we described a therapeutic approach for eradication of HCV infected cells that is based on protein delivery of two NS3 protease-activatable recombinant toxins we named "zymoxins". These toxins were inactivated by fusion to rationally designed inhibitory peptides via NS3-cleavable linkers. Once delivered to cells where NS3 protease is present, the inhibitory peptide is removed resulting in re-activation of cytotoxic activity. The zymoxins we described suffered from two limitations: they required high levels of protease for activation and had basal activities in the un-activated form that resulted in a narrow potential therapeutic window. Here, we present a solution that overcame the major limitations of the "first generation zymoxins" by converting MazF ribonuclease, the toxic component of the E. coli chromosomal MazEF toxin-antitoxin system, into an NS3-activated zymoxin that is introduced to cells by means of gene delivery. We constructed an expression cassette that encodes for a single polypeptide that incorporates both the toxin and a fragment of its potent natural antidote, MazE, linked via an NS3-cleavable linker. While covalently paired to its inhibitor, the ribonuclease is well tolerated when expressed in naïve, healthy cells. In contrast, activating proteolysis that is induced by even low levels of NS3, results in an eradication of NS3 expressing model cells and HCV infected cells. Zymoxins may thus become a valuable tool in eradicating cells infected by intracellular pathogens that express intracellular proteases.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 2%
Denmark 1 2%
Canada 1 2%
Unknown 45 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 27%
Researcher 9 19%
Student > Bachelor 5 10%
Student > Master 4 8%
Professor > Associate Professor 3 6%
Other 6 13%
Unknown 8 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 40%
Biochemistry, Genetics and Molecular Biology 11 23%
Medicine and Dentistry 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Immunology and Microbiology 2 4%
Other 3 6%
Unknown 6 13%